Eli Lilly Reports Stellar Q1 Performance

Eli Lilly announced a remarkable 45% increase in first-quarter revenue, reaching $12.73 billion for fiscal 2025. This surge was primarily driven by the robust sales of its weight-loss and diabetes medications, Mounjaro and Zepbound.

Financial Highlights and Future Plans

The company also disclosed a net income of $2.76 billion, marking a 23% rise compared to the previous year. Despite facing $1.57 billion in acquired in-process R&D charges, earnings per share stood strong at $3.06.

CEO David Ricks emphasized the success of the company's oral GLP-1 candidate, forgilzumab, and confirmed the revenue guidance for the year to be between $58 billion and $61 billion. Additionally, Eli Lilly revealed ambitious plans to expand its US manufacturing capabilities with a $50 billion investment to cater to the escalating demand.